Industry | 2019.05.20
SoniVie Appoints Charles Carignan, MD, Chief Executive Officer and Announces Upcoming Presentation of TIVUS™ Clinical Trial Data at EuroPCR 2019
Medical device industry veteran will advance clinical and commercial development of SoniVie’s percutaneous ultrasound pulmonary artery denervation treatment for pulmonary arterial hypertension - - Results of TROPHY1, a multi-center, international clinical trial of TIVUS in patients with pulmonary arterial hypertension, will be presented at leading interventional cardiovascular medicine conference -
(PRWeb May 20, 2019)
Read the full story at https://www.prweb.com/releases/sonivie_appoints_charles_carignan_md_chief_executive_officer_and_announces_upcoming_presentation_of_tivus_clinical_trial_data_at_europcr_2019/prweb16322426.htm
For more information, please visit
https://www.prweb.com/releases/sonivie_a[...]europcr_2019/prweb16322426.htm
